64th ASH Annual Meeting and Exposition: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents

Symposia: Chronic Myeloid Leukemia: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Lymphoid Leukemias, ALL, adult, Non-Biological therapies, Clinical Research, CML, Chemotherapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, Lymphoid Malignancies, Myeloid Malignancies, Study Population, Human

217-219 (Ernest N. Morial Convention Center)

Moderators:

David T Yeung, MBBS, PhD, BSc, FRACP, FRCPA, ARRAY(0xe1870a0) and Michael Mauro, MD, Memorial Sloan Kettering Cancer Center

Disclosures:

Yeung: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mauro: AbbVie, Bristol Myers Squibb, Novartis, Pfizer, Takeda: Consultancy, Honoraria, Other: Travel, accommodation, expenses , Research Funding; Sun Pharma/SPARC: Research Funding.

9:30 AM

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML

David T Yeung, MBBS, PhD, BSc, FRACP, FRCPA^1,2,3, Naranie Shanmuganathan, MBBS, FRACP, FRCPA^4,5,6, John Reynolds, PhD⁷^*, Susan Branford, PhD⁸, Mannu Walia, Msc PhD⁹^*, Agnes S. M. Yong, MD, PhD¹⁰, Jake Shortt, FRACP, FRCPA, PhD^11,12, Kate Burbury, MBBS, FRACP, FRCPA, DPhil¹³^*, Nicholas Viiala, MBBS FRACP FRCPA^14,15^*, Ilona Cunningham, MBBS, FRACP, FRCPA¹⁶, David M. Ross, MBBS, PhD, FRACP, FRCPA¹⁷^*, Rosemary Harrup, MBBS FRACP FRCPA¹⁸^*, Matthew Wright, MBBS, FRCPA, FRACP¹⁹^*, Cecily Forsyth, MBBS, FRACP, FRCPA²⁰, Alwyn Bernard D'Souza, MBBS, FRACP, FRCPA²¹^*, Robin J Filshie, MBChB, PhD, FRACP, FRCPA²², Peter J. Browett^23,24, Steven W Lane, MD, PhD^25,26, Carolyn Grove, MBBS, PhD²⁷^*, Andrew Grigg, MBBS, MD, FRACP, FRCPA²⁸^* and Timothy Hughes, MD, MBBS, FRACP, FRCPA^2,3,29

¹Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
²Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
³Adelaide Medical School, The University of Adelaide, Adelaide, Australia
⁴Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
⁵Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
⁶School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia
⁷The Alfred Hospital and Monash University, Melbourne, VIC, Australia
⁸Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia
⁹Australasian Leukaemia and Lymphoma Group, Richmond, Australia
¹⁰Haematology, Royal Perth Hospital and University of Western Australia, Perth, Australia
¹¹Monash Haematology, Monash Health, Clayton, VIC, Australia
¹²School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia
¹³Peter MacCallum Cancer Centre, Melbourne, Australia
¹⁴University of NSW, Sydney, Australia
¹⁵Liverpool Hospital, Sydney, Australia
¹⁶Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
¹⁷Haematology, Flinders Medical Centre and Flinders University, Bedford Park, SA, Australia
¹⁸Royal Hobart Hospital, University of Tasmania, Tasmania, Australia
¹⁹Department of Haematology, Fiona Stanley Hospital, Perth, Australia
²⁰Gosford Hospital and Newcastle University, Gosford, NSW, Australia
²¹Capital Coast Health and Otago University, Wellington, New Zealand
²²Department of Hematology, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia
²³Department of Molecular Medicine and Pathology, University of Auckland School of Medicine, Auckland, New Zealand
²⁴Auckland City Hospital, Grafton, New Zealand
²⁵Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
²⁶Cancer Program, Queensland Institute of Medical Research, Brisbane, Australia
²⁷Department of Haematology, Sir Charles Gairdner Hospital & PathWest, Nedlands, Australia
²⁸Department of Clinical Haematology, Austin Health, Heidelberg, VIC, Australia
²⁹South Australian Health and Medical Research Institute SAHMRI, Adelaide, SA, Australia

9:45 AM

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, MD¹, Timothy Hughes, MD, MBBS, FRACP, FRCPA², Jan Geissler³^*, Dong-Wook Kim, M.D., Ph.D.⁴, Elza Lomaia, MD, PhD⁵^*, Jiri Mayer⁶, Anna G. Turkina, MD, Ph.D⁷^*, Sarah Hurwicz Kogut⁸^*, Ana Paula Torres Cardoso, PhD, MD⁹^*, Monali Sura⁹^* and Giuseppe Saglio, MD¹⁰

¹Georgia Cancer Center, Augusta, GA
²South Australian Health and Medical Research Institute SAHMRI, Adelaide, SA, Australia
³Patvocates, Munich, Germany
⁴Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, Korea, Republic of (South)
⁵Almazov National Medical Research Centre, St. Petersburg, Russian Federation
⁶Masaryk University and University Hospital Brno, Brno, Czech Republic
⁷National Medical Research Center for Hematology, Moscow, Russian Federation
⁸ICON, plc, Dublin, Ireland
⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
¹⁰Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

10:00 AM

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang¹^*, Zongru Li²^*, Ya-Zhen Qin³^*, Ting Zhao²^*, Bingcheng Liu⁴^*, Zi Chen^5,6^*, Qian Niu^5,6^*, Lichuang Men^5,6^*, Hengbang Wang, PhD^5,6^*, Dajun Yang^7,8^*, Yifan Zhai^6,8,9 and Xiao-Jun Huang³^*

10:15 AM

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Elias Jabbour, MD¹, Paul B. Koller, MD², Vivian G. Oehler, MD³^*, Omer H Jamy, MD⁴, Sudipto Mukherjee, MD, PhD, MPH⁵, Anthony M. Hunter, MD⁶^*, Maria R. Baer, MD⁷, Joseph T. Beck, MD, FACP⁸^*, Zi Chen⁹^*, Huanshan Guo¹⁰^*, Lei Fu¹¹^*, Lichuang Men⁹^*, Hengbang Wang, PhD⁹^*, Dajun Yang^9,10,11^*, Yifan Zhai^9,11,12, Hagop Kantarjian, MD¹³, Lixin Jiang, MD¹¹^* and Cunlin Wang, MD¹¹^*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
³Fred Hutchinson Cancer Center, Seattle, WA
⁴Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
⁵Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
⁶Emory University School of Medicine, Atlanta, GA
⁷University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
⁸Highlands Oncology Group, Fayetteville, AR
⁹Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
¹⁰Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China
¹¹Ascentage Pharma Group Inc., Rockville, MD
¹²Healthquest Pharma Co. Ltd., Guangzhou, China
¹³Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 AM

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang¹^*, Zongru Li²^*, Yue Hou³^*, Yu Hu⁴^*, Weiming Li⁴^*, Xiaoli Liu⁵^*, Na Xu⁵^*, Yanli Zhang⁶^*, Yongping Song⁶^*, Li Meng⁷^*, Zhenya Hong⁷^*, Bingcheng Liu⁸^*, Yan Li⁹^*, Suning Chen¹⁰^*, Mengxing Xue¹¹^*, Huanling Zhu¹²^*, He Li¹²^*, Xin Du¹³^*, Jin Lou¹³^*, Xiaohan Zhang¹³^*, Yang Liang, MD, PhD¹⁴, Yu-Jun Dai¹⁴^*, Zi Chen¹⁵^*, Qian Niu¹⁵^*, Lichuang Men¹⁵^*, Dajun Yang^15,16^*, Yifan Zhai^16,17 and Xiao-Jun Huang³^*

¹Peking University Institute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
²Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
³Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China
⁴Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁵Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
⁶Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
⁷Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁸Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
⁹Institute of Hematology and Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Tianjin, China
¹⁰National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
¹¹Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
¹²Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
¹³Division of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
¹⁴Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
¹⁵Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China
¹⁶Ascentage Pharma Group Inc., Rockville, MD
¹⁷Healthquest Pharma Co. Ltd., Guangzhou, China

10:45 AM

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Jorge E. Cortes, MD¹, Tapan Saikia, MD², Dong-Wook Kim, M.D., Ph.D.³, Yesid Alvarado, MD⁴, Franck E. Nicolini, MD, PhD⁵, Krishnakumar Rathnam, MD, DM⁶^*, Navin Khattry, MD, DM⁷^*, Sachin Punatar, MD, DM⁸^*, Jane F. Apperley, FRCP, FRCPath, MB⁹, Aude Charbonnier, MD¹⁰^*, Michael Deininger, MD¹¹, Hugues de Lavallade, MD¹²^*, Nikki Granacher, MD¹³^*, Carlo Gambacorti-Passerini, MD¹⁴, Alessandro Lucchesi, MD, PhD¹⁵^*, Michael Mauro, MD¹⁶, Peter Vandenberghe, MD, PhD¹⁷, Gregor Verhoef, MD, PhD¹⁸^*, Andrew R. Whiteley, MD¹⁹, Arijit Nag, MD²⁰^*, Shashikant Apte, MD, FRCPA²¹, Siu-Long Yao, MD²², Sandeep Inamdar, MBBS²³^*, Ruchika Irene Dillu, MD²³^*, Jayasree Sreenivasan, MSc²³^* and Geetanjali Chimote, MBBS, PhD²²^*

¹Georgia Cancer Center, Augusta, GA
²Prince Aly Khan Hospital, Mumbai, India
³Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, Korea, Republic of (South)
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Centre Hospitalier Lyon Sud, LYON Cedex 03, France
⁶Lake Area,Melur Main Rd, Meenakshi Mission Hospital and Research Centre, Tamil Nadu, India
⁷Department of Bone Marrow Transplant, ACTREC, Tata Memorial Centre, Navi Mumbai, India
⁸Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
⁹Centre for Haematology, Imperial College London at the Hammersmith Hospital, London, ENG, United Kingdom
¹⁰Departement d'Hematologie, Institut Paoli Calmettes, Marseille, France
¹¹University of Utah, Salt Lake City, UT
¹²King's College Hospital NHS Foundation, London, United Kingdom
¹³Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
¹⁴Dept of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
¹⁵Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy
¹⁶Memorial Sloan Kettering Cancer Center, New York, NY
¹⁷University of Leuven, Leuven, Belgium
¹⁸Department of Hematology, UZ Leuven, Leuven, Belgium
¹⁹Baylor University Medical Center, Dallas, TX
²⁰Tata Medical Center, Kolkata, India
²¹Pune’s Sahyadri Hospital, Maharashtra, India
²²Sun Pharmaceutical Industries, Inc., Princeton, NJ
²³Sun Pharma Advanced Research Company Ltd, Mumbai, India

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

632.O1.6 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents